Biomarker directed therapies in biliary tract cancers

preview_player
Показать описание
Approximately 40% of biliary tract cancer harbor gene alterations that can be targeted with precision-based medicines. James J. Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the targetable mutations in biliary tract cancer and the future of the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
  1. VJOncology
  2. Speaker: James J. Harding
  3. Institution: Memorial Sloan Kettering Cancer Center
  4. Event: ASCO 2022
  5. Format: Interview
  6. Subject: Gastrointestinal Cancer
Рекомендации по теме
Biomarker directed therapies 0:01:08

Biomarker directed therapies in biliary tract cancers

Future developments in 0:02:05

Future developments in immunotherapy for treatment of biliary tract cancer

Patient Case: How 0:05:00

Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

For Cholangiocarcinoma Patients, 0:03:32

For Cholangiocarcinoma Patients, Biomarkers Matter

Management of biliary 0:04:51

Management of biliary tract cancers with targeted therapies

Advances in treating 0:01:23

Advances in treating biliary tract cancers with targeted therapies

Molecular testing for 0:00:27

Molecular testing for cholangiocarcinoma

Biomarker analysis of 0:02:40

Biomarker analysis of nivolumab in patients with advanced refractory biliary tract cancer

Evaluating the efficacy 0:01:24

Evaluating the efficacy of targeted treatments in biliary tract cancers

For healthcare providers 0:04:08

For healthcare providers treating cholangiocarcinoma, Biomarkers Matter

Cholangiocarcinoma patient Matt 0:04:11

Cholangiocarcinoma patient Matt Reidy's biomarker story

Biomarkers Matter for 0:03:59

Biomarkers Matter for Cholangiocarcinoma Patients - Mandarin

Webinar: Role of 0:45:20

Webinar: Role of CEACAM6 as a Biomarker in Cholangiocarcinoma

Embracing the Era 1:27:19

Embracing the Era of Individualized Therapy in Advanced Biliary Cancers

Hepatic, Biliary, and 0:03:14

Hepatic, Biliary, and Pancreatic Cancer Updates: 2023 Best of GI

Cholangiocarcinoma patient Sharon 0:03:30

Cholangiocarcinoma patient Sharon Hockenberry's biomarker story

Unveiling the Mysteries 0:04:08

Unveiling the Mysteries of Biliary Tract Cancer: A Deep Dive into Cholangiocarcinoma

Gallbladder and Bile 0:01:01

Gallbladder and Bile Duct Cancers Targeted Therapy: Dr. Martin Palmeri | Messino Cancer Centers

Evolution of HER2-Targeted 0:24:04

Evolution of HER2-Targeted Therapy in Biliary Tract Cancer

Cholangiocarcinoma patient Julie 0:05:14

Cholangiocarcinoma patient Julie Thole's biomarker story

Cholangiocarcinoma patient John 0:04:39

Cholangiocarcinoma patient John Pierce's biomarker story

For Cancer Patients, 0:03:21

For Cancer Patients, Biomarkers Matter

Unveiling Targeted Therapy: 0:23:17

Unveiling Targeted Therapy: Revolutionizing Cancer Treatment

The emerging role 0:05:56

The emerging role of immunotherapy in cholangiocarcinoma